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Abstract
Introduction: Delirium affects up to 80% of patients admitted to intensive care units (ICUs) and contributes to
increased morbidity and mortality. Haloperidol is the gold standard for treatment, although quetiapine has been
successfully used in the management of delirium.
Methods: We conducted a retrospective study of patients admitted to the ICU between February 2008 and May
2010 who were prescribed quetiapine by the attending clinician. Data collected included demographics, history of
drug and/or alcohol dependence, ICU and hospital length of stay, length of mechanical ventilation and the
duration of treatment with sedatives and medications for delirium. The daily dose of quetiapine was recorded.
Hyperactive or mixed delirium was identified by a validated chart review and a Richmond Agitation Sedation Scale
(RASS) score persistently greater than 1 for 48 hours despite therapy.
Results: Seventeen patients were included. Delirium onset occurred after a median of five days. Patients were
being given at least four agents for delirium prior to the introduction of quetiapine, and they had a median RASS
score of 3. Quetiapine was initiated at a 25 mg daily dose and titrated to a median daily dose of 50 mg. The
median duration of delirium prior to quetiapine therapy was 15 days. Quetiapine commencement was associated
with a reduction in the need for other medications (within 0 to 6 days) and resolution of delirium within a median
of four days. Adverse events included somnolence and transient hypotension.
Conclusions: This case series provides an initial effort to explore a possible role for quetiapine in the management
of refractory hyperactive and mixed ICU delirium.
Introduction
Delirium is an acute, reversible and fluctuating altera-
tion in consciousness and mentation. It is reported in
up to 33% of acutely hospitalised patients [1] and in
20% to 80% of patients admitted to the intensive care
unit (ICU) [2-6]. Delirium may manifest as a reduction
in the level of consciousness with increased somnolence,
decreased cognition and responsiveness or as a state of
hypervigilance, agitation and confusion. Delirium may
also fluctuate between these two extremes. Delirium has
a significant impact upon patients within the ICU, and
its presence has been associated with increased mortal-
ity, increased length of ICU and hospital stay, increased
length of ventilator dependence and increased sedation
use [2,7-9]. Delirium is also a significant risk factor for
the development of post-ICU cognitive dysfunction,
including posttraumatic stress disorder [10]. Multiple
factors contribute to the development of delirium,
including preexisting cognitive dysfunction, alcohol and/
or drug withdrawal, sedative use, altered or inadequate
sleep, painful procedures, lack of a focal point, infection,
shock states and disordered physiology (for example,
hypercapnoea or hypoxia) [10,11].
Managing patients with delirium can be extremely
challenging. The optimal management of delirium
requires a calm environment, sleep, good hygiene, cor-
rection of any underlying contributing factors and mini-
mising sedative use [12]. These can be challenging in
the ICU, given the environment and the patient acuity.
Agitated patients may cause harm to themselves by
inadvertently removing endotracheal tubes, venous
access or invasive monitoring. Hence, to preserve
* Correspondence: catherine.mckenzie@gstt.nhs.uk
1Institute of Pharmaceutical Sciences, Kings College London and Department
of Pharmacy Guy’s and St Thomas’ NHS Foundation Trust, Westminster
Bridge Road, London SE1 7EH, UK
Full list of author information is available at the end of the article
Wan et al. Critical Care 2011, 15:R159
http://ccforum.com/content/15/3/R159
© 2011 Wan et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.patient safety, drug therapy including haloperidol, cloni-
dine, benzodiazepines or propofol is commonly used.
Haloperidol has remained the gold standard of drug
therapy for ICU delirium, despite significant limitations
due to adverse events, including QTc prolongation (with
the potential to trigger ventricular tachycardia, especially
Torsades de Pointes), hypotension and extrapyramidal
side effects. Haloperidol’s status as the gold standard for
delirium therapy is predominantly a result of historical
precedent [13]. However, some investigators have
reported that haloperidol may prolong delirium in the
ICU population [14-16]. To ensure maximum effect and
minimise adverse events, it has been advised that halo-
peridol should be administered in small, frequent doses
(0.5 to 1 mg every two to four hours) [17,18]. This can
be difficult to achieve in clinical practice, and thus it is
possible that poor administration contributes to delir-
ium and agitation or results in an increase in adverse
events as a result of this treatment [19].
Quetiapine, an atypical antipsychotic drug, has
demonstrated efficacy in psychiatry and has been used
to treat conditions such as acute schizophrenia, mania,
depression and bipolar disorder [20]. Recent reports
have also demonstrated that quetiapine can be of benefit
in the management of delirium in older medical patients
[21]. Quetiapine has ‘loose’ or low binding at D2 recep-
tors, which has been reported to be favourable in delir-
ium management [22,23]. In addition, quetiapine has
several pharmacokinetic properties that make it poten-
tially advantageous in the ICU. It is administered every
12 hours, has a relative short half-life of 7 hours (12
hours for its active metabolite norquetiapine) [19] and is
readily titratable, and it causes a lower incidence of QTc
prolongation and fewer extrapyramidal symptoms than
haloperidol [18,20,24].
In a recent randomised, controlled trial, quetiapine
was shown to be efficacious when added to haloperidol
in the management of delirium in a tightly defined ICU
population [25]. The successful use of quetiapine in
refractory hyperactive delirium in the ICU has also been
previously reported in a case series of five patients [26].
It has been the usual practice in our institution to
administer quetiapine to patients with hyperactive or
mixed delirium refractory to other management
strategies.
Materials and methods
This review of a retrospective case series was approved
by the Guys and St Thomas’ NHS Foundation Trust
Clinical Audit Group (registration number 2023).
Patient consent was waived, and the review was
unfunded. The case series was carried out in a 30-bed
level 3 ICU that has more than 1,200 admissions
annually. We included the case notes of patients
admitted from February 2008 to May 2010 who were
prescribed quetiapine by the attending clinician for
hyperactive or mixed delirium. Patients were excluded if
they were taking quetiapine for a preexisting psychiatric
illness. The data collected included demographic data,
admitting diagnosis, drug and/or alcohol dependence,
ICU and hospital length of stay, length of mechanical
ventilation, the duration of sedatives and/or opioids to
control agitation, and support ventilation and other
therapies used to specifically manage delirium or agita-
tion (haloperidol or clonidine). The dose of quetiapine
at the initiation of therapy and subsequent dose changes
were recorded. Adverse effects commonly observed dur-
ing quetiapine therapy were recorded, and these
included sedation, hypotension, extrapyramidal side
effects and QTc prolongation [20]. The median daily
Richmond Agitation Sedation Scale (RASS) score was
calculated, and a validated retrospective chart review
was performed to identify delirium [27]. Refractory
hyperactive or mixed delirium was retrospectively iden-
tified if the patient’s RASS score was greater than 1 for
more than 48 hours, the daily validated chart review
indicated the presence of an acute confusional state (for
example, delirium, mental status change, inattention,
disorientation, hallucinations, agitation or inappropriate
behaviour) and two or more agents were used prior to
the introduction of quetiapine known to treat delirium.
The validated chart review was undertaken by a junior
doctor, and the results were confirmed by a senior clini-
cal pharmacist.
Results
A total of 19 patients were prescribed quetiapine, 2 of
whom were excluded because quetiapine had been pre-
scribed for chronic psychiatric indications; hence 17
patients were included in thec a s es e r i e s( T a b l e1 ) .F i f -
teen patients were male with a mean patient age of 59
years. Eight patients had a history of drug or alcohol
abuse. The validated chart review confirmed in all
cases; alcohol or drug withdrawal was not believed to
be the cause of delirium as viewed by the attending
clinician.
Prior to the introduction of quetiapine, the patients
had a median RASS score of 3 and were being treated
with two or more drugs for delirium, and there was
consistent documentation of an acute confusional state
identified in the validated chart review. The median
time until delirium onset was day 5 from ICU admission
(Table 1), and the median duration of refractory hyper-
active or mixed delirium was 15 days prior to the intro-
duction of quetiapine (Table 2). Prior to the
commencement of quetiapine therapy, all patients had
been taking four or five agents to control their delirium
and agitation (Table 2).
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route at a daily dose of 25 mg (normally administered in
12-hourly divided doses) for all patients, and the dose
was titrated by the attending clinician. The median total
daily dose prescribed was 50 mg (range, 12.5 to 400
mg). Following the introduction of quetiapine, the
patients had a reduced need for other medications and
experienced resolution of refractory hyperactive or
mixed delirium within a median of four days (Table 2).
Adverse effects were recorded in four patients. One
patient developed QTc prolongation, which was defined
as an increase of more than 60 milliseconds from
baseline. Excessive somnolence was noted in one
patient, and transient hypotension was noted in the two
remaining patients but was not significant enough to
warrant discontinuation of quetiapine. No extrapyrami-
dal symptoms were observed.
Quetiapine was ceased in 10 patients before they left
the ICU. In four patients, it was ceased on the ward fol-
lowing discharge from the ICU. One patient was dis-
charged to home, and two were discharged to their local
hospitals prior to cessation of quetiapine. When or if
they stopped taking quetiapine is not known.
Discussion
In this retrospective case series, we found that there is a
temporal association between the commencement of
quetiapine therapy and the resolution of refractory
hyperactive or mixed delirium. Patients had been in a
hyperactive or mixed delirium for a median of 15 days
prior to quetiapine initiation, but this state resolved
within a median of 4 days after the start of quetiapine
treatment. Once quetiapine therapy was commenced,
patients were weaned rapidly from most other medica-
tions over a median of zero to two days, with propofol
treatment continued for a median of six days. The
patients who were given quetiapine were considered to
have refractory mixed or hyperactive delirium and
required the attending clinicians to use challenging
management strategies. Quetiapine was well tolerated,
with transient hypotension, somnolence and asympto-
matic QTc prolongation recorded for only four patients.
Quetiapine was ceased in 10 patients before they left the
ICU and in another 4 patients before they left the hospi-
tal. Given that this is an uncontrolled case series, these
data cannot provide proof of efficacy. However, it does
encourage the development of randomised, controlled
trials of quetiapine in this patient population.
The patients who received quetiapine in this case ser-
ies are recognised as the group at the highest risk of
developing hyperactive or mixed delirium which is
refractory to treatment [7]. In particular, this series con-
tained mixed medical and surgical patients who predo-
minantly presented with sepsis or severe respiratory
Table 1 Patient characteristics
a
Characteristics Data
Number of patients 17
Mean age, years (range) 59 (30 to
85)
Males, n (%) 15 (88%)
Number of ventilated patients, n (%) 16 (94.1%)
Tracheotomy 12 (75%)
Intubated 4 (25%)
Median total length of stay in ICU, days (range) 41 (16 to
235)
Location before ICU, n (%)
Home 9 (52.9%)
Another hospital 4 (23.5%)
Ward 4 (23.5%)
Case mix, n (%)
Medical 10 (59%)
Surgical 7 (41%)
Admission diagnosis, n (%)
Sepsis/acute respiratory distress syndrome 8 (47%)
Surgery 4 (23.5%)
Myocardial infarction 4 (23.5%)
Other 1 (6%)
Alcohol excess, n (%) 6 (35.2%)
b
Substance abuse, n (%) 2 (11.7%)
b
Median days to delirium onset after admission to ICU, n
(range)
5 (0 to 20)
aICU, intensive care unit.
bOne patient had a history of substance abuse and
alcohol excess.
Table 2 Clinical outcomes and relevant medication therapy
Outcomes Median pre-quetiapine days, n (range) Median post-quetiapine days, n (range)
Duration of refractory delirium 15 (3 to 48) 4 (2 to 29)
Duration of ventilatory support 20.5 (1 to 58) 11 (3 to 17)
Duration of ventilatory support since RASS score 0 achieved - 2 (1 to 11)
Haloperidol n = 14 6 (1 to 37) 0.5 (0 to 7)
Lorazepam, n = 10 9.5 (1 to 19) 1 (0 to 7)
Propofol, n = 17 17 (5 to 27) 6 (0 to 18)
Opioids (fentanyl/alfentanil), n = 17 18 (7 to 34) 0 (0 to 16)
Clonidine, n = 14 9.5 (2 to 33) 2 (0 to 16)
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drug and/or alcohol dependence. A recent randomised,
controlled trial in ICUs that demonstrated the benefits
of quetiapine therapy in patients with delirium demon-
strated resolution of delirium within a median of one
day [25]; however, that study was performed in a more
homogeneous patient group with a shorter duration of
delirium and fewer risks for refractory delirium than the
current case series. It is therefore encouraging that the
delirium in the current series resolved soon after the
commencement of quetiapine. This could potentially be
associated with the administration of quetiapine itself,
the concomitant reduction in opioids and other seda-
tives or by chance alone [7].
The quetiapine doses used in our case series were
initially lower than those reported in the recent study by
Devlin and colleagues [25], which commenced at a total
of 100 mg daily administered in 12-hourly divided
doses. The median maximum total daily dose of 50 mg
reported in our case series is also lower than those in
other studies, in which median maximum total daily
doses of 400 mg were used [28]. The two patients who
received a total daily dose greater than 200 mg in our
series had a history of alcohol dependence, which is
known to require an increased dose of psychotropic
medications [6]. Although the results of the current ser-
ies are not conclusive, it is encouraging that lower doses
could be prescribed, which may provide guidance for
future studies.
Few adverse events were noted overall in the case
notes of these patients. Problems were predominantly
related to somnolence and postural hypotension, which
are similar to those described in the literature [20,24].
Despite the presence of hypotension, quetiapine treat-
ment was continued as the attending clinician consid-
ered that other causes for hypotension were present and
the hypotension resolved spontaneously. One patient
developed a prolonged QTc interval, which resulted in
discontinuation of the drug. This patient was receiving
concomitant fluconazole, an inhibitor of the cytochrome
P450 isoenzyme CYP3A4 that also metabolises quetia-
pine. Concurrent use of fluconazole increases quetiapine
levels, thus the QTc prolongation could be considered
the result of a drug interaction rather than an adverse
effect [29]. No episodes of extrapyramidal side effects
were noted; however, an extrapyramidal side effect rat-
ing scale is not routinely used in our institution. The
retrospective assessment of adverse events can be very
difficult, and it is likely that adverse events were under-
recognised, especially given that the rate of adverse
events was lower than the rates reported in the litera-
ture [28,30].
In this case series, the median daily RASS score, use of
more than two medications and a validated case note
review were used to evaluate hyperactive or mixed delir-
ium. The use of a validated case note review is an
accepted method of establishing the clinician’so p i n i o n
that a state of delirium exists, although considerable
expertise is required to undertake it [27]. In this case ser-
ies, the validated chart review was undertaken by a junior
doctor and was then confirmed by a senior clinical phar-
macist in all cases. The RASS is a subjective 11-point
scale that has discrete criteria for levels of sedation and
agitation. It has been reported to have high reliability and
validity for sedation and agitation in medical, surgical,
ventilated, nonventilated, sedated and nonsedated ICU
patients and is commonly used in the UK [31,32]. The
RASS score is routinely measured hourly, providing a
longitudinal measure of agitation and sedation [33]. The
RASS is not a delirium scoring system, and agitation may
be due to a number of reasons (including pain or physio-
logical dysfunction). However, agitation is a common fea-
ture of hyperactive or mixed delirium, and the
combination of the RASS score with the validated case
note review should identify patients in whom delirium is
believed to exist by the attending clinician. Specific delir-
ium scoring systems such as the confusion assessment
method (CAM)-ICU have a higher reported sensitivity
and specificity and higher interrater reliability ( =0 . 9 6 )
for the assessment of delirium [34]. However, our ICU,
l i k em a n yi nt h eU K ,d o e sn o tu s eC A M - I C Uo ra n y
other dedicated delirium screening checklist (for exam-
ple, the intensive care delirium screening checklist
(ICDSC)) in routine clinical practice [32].
This study comprised a small, uncontrolled, retrospec-
tive, single-centre case series and has significant poten-
tial limitations. Selection bias is clearly a problem, given
that patients received quetiapine on the basis of the
treating physician’s opinion. The cohort of patients was
small, and no control group was used. Although the
data suggest a temporal relationship between the initia-
tion of quetiapine therapy and the resolution of delir-
ium, no causal relationship can be established. It is
entirely possible that the patients’ delirium was resolving
a tt h es a m et i m et h a tq u e t i a p i n ew a sc o m m e n c e d .F o l -
low-up was incomplete, and no formal neuropsychologi-
cal assessment was made following discharge from the
I C U ;h e n c en oc o m m e n tc a nb em a d er e g a r d i n gt h e
longer-term sequelae of delirium and posttraumatic
stress disorder. Given the retrospective, uncontrolled
nature of the review, other unrecognised sources of bias
might exist. All of these methodological weaknesses
could be addressed by a suitably powered, prospective,
randomised, placebo-controlled trial. Any prospective
evaluation of delirium should include validated tools
(ICDSC or CAM-ICU) to support the diagnosis of delir-
i u ma n dt h ep o s s i b l ee f f e c t so fq u e t i a p i n ei nt h et r e a t -
ment of delirium.
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In this article, we describe a retrospective case series in
which we studied the clinical course of patients with dif-
ficult-to-manage hyperactive or mixed delirium who
received quetiapine at the request of the attending clini-
cian. The commencement of quetiapine treatment might
be temporally associated with the resolution of hyperac-
tive and mixed delirium and a reduction in sedative
dose. Nonetheless, the absence of controls does not
allow us to draw any definitive conclusions regarding
the effects of quetiapine in patients with hyperactive and
mixed delirium. The low doses used and the low adverse
event rate in our case series will be helpful by providing
guidance for future prospective trials.
Key messages
￿ Quetiapine might be an effective therapy in diffi-
cult-to-treat patients with hyperactive and mixed
delirium.
￿ Quetiapine may be efficacious at doses lower than
those reported in the literature.
￿ Quetiapine’s effectiveness in this patient group
should be tested further in a controlled study.
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